引领药物研发与定量药理学
专业咨询
Drug Development and Pharmacometrics Leadership
Publication
发表文章
[Exposure-Response Analysis] Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
2023-02-16
Abstract
Purpose: A novel single-dose regimen of 300 mg tremelimumab in combination with durvalumab [Single Tremelimumab Regular Interval Durvalumab (STRIDE)] has demonstrated a favorable benefit-risk profile in the phase I/II Study 22 (NCT02519348) and phase III HIMALAYA study (NCT03298451). This study evaluated the pharmacokinetics, exposure-response, and exposure-pharmacodynamics relationships of tremelimumab in patients with unresectable hepatocellular carcinoma (uHCC).
Patients and methods: A previous tremelimumab population pharmacokinetic model was validated using data from parts 2 ......
[Exposure-Response Analysis] Exposure-Response Efficacy and Safety Analyses of Tremelimumab as Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma (uHCC)
2021-01-22
Abstract
Background: In a phase II study in uHCC (Study 22, NCT02519348), a novel, priming combination regimen of tremelimumab (T; anti-CTLA-4) and durvalumab (D; anti-PD-L1) (T300+D) has shown favorable clinical activity vs each agent as monotherapy or vs another combination (T75+D). The analyses presented here assess the pharmacokinetics (PK) and relationships between tremelimumab exposure, as monotherapy or in combination, and safety, efficacy, and pharmacodynamics (PD) in this study. Methods: Overall, 216 pts were included in these analyses (T, n=65; T300+D, n=72; T75+D, n=79). Safety, an......
[Exposure-Response Analysis] Exposure-Response Relationship of the Bruton Tyrosine Kinase Inhibitor, Zanubrutinib (BGB-3111) in Patients with Hematologic Malignancies.
2019-11-13
Background:
Zanubrutinib (BGB-3111) is a highly selective, potent, irreversible inhibitor of Bruton tyrosine kinase (BTK), currently in phase 3 development for the treatment of hematologic malignancies, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and Waldenström's macroglobulinemia (WM). In a dose escalation study evaluating doses of 40, 80, 160, and 320 mg once daily and 160 mg twice daily, no dose limiting toxicities were observed and maximum tolerated dose (MTD) was not established. Objective responses have been observed in patients with various B-cell malign......
[Exposure-Response Analysis] Exposure-Response Relationship of the Bruton Tyrosine Kinase Inhibitor, Zanubrutinib (BGB-3111) in Patients with Hematologic Malignancies
2019-11-13
Abstract
Background:
Zanubrutinib (BGB-3111) is a highly selective, potent, irreversible inhibitor of Bruton tyrosine kinase (BTK), currently in phase 3 development for the treatment of hematologic malignancies, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and Waldenström's macroglobulinemia (WM). In a dose escalation study evaluating doses of 40, 80, 160, and 320 mg once daily and 160 mg twice daily, no dose limiting toxicities were observed and maximum tolerated dose (MTD) was not established. Objective responses have been observed in patients with various B-c......
[Exposure-Response Analysis] Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors.
2019-09-30
Background
Tislelizumab, an investigational humanized IgG4 monoclonal antibody, was engineered to minimize binding to FcgR on macrophages in order to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. Tislelizumab exposure-response (E-R) relationships for efficacy and safety endpoints in subjects with advanced tumors were evaluated to inform the benefit-risk assessment and to explore the feasibility of alternative dosing schedules.
Methods
The analyses used data from patients with advanced solid tumors (n = 745) and class......
地址:上海市浦东区张杨路707号生命人寿大厦3201A
电话:400-102-3201
[学术交流] 第二届定量药理学中R语言应用(初级)线上研讨会成功举办
2022-06-06
[公司动态] 第二届Certara Phoenix NLME产品研讨会
2019-02-16
[学术交流] 第一届Certara Phoenix NLME 产品研讨会于上海成功举办
2018-05-15
[学术交流] 第一届Certara Phoenix NLME产品研讨会通知
2018-04-05
[学术交流] 第一届 Certara Phoenix 药动学药效学模型研讨会于上海顺利召开
2018-03-19